A modified version of CGRP called ssCGRP binds its receptor with ultrahigh affinity (0.2 nM vs 74 nM for natural CGRP) and sustains signaling far longer, offering a blueprint for next-generation long-acting migraine and pain therapeutics.
76-min residence timeThe ssCGRP antagonist fragment stayed bound to the CGRP receptor for 76 minutes compared to just 5 seconds for the natural CGRP fragment — a 900-fold increase in receptor occupancy duration.
What the researchers found
ssCGRP bound the CGRP receptor with 0.2-0.25 nM affinity regardless of G protein coupling state (vs. 3-74 nM for wildtype CGRP) and had a 76-minute receptor residence time versus 5 seconds for wildtype fragments.
Why it matters
Current CGRP-targeting migraine drugs block the receptor entirely. Understanding the precise binding mechanism — and having an ultrahigh-affinity variant — opens the door to more nuanced therapeutics that could modulate CGRP signaling with greater precision and duration rather than simply shutting it off.
How the study worked
In vitro study using nanoBRET receptor binding assays, cAMP biosensor signaling assays, and equilibrium reaction network mathematical modeling to characterize wildtype CGRP and ssCGRP variant binding kinetics at the CGRP receptor.
What this study cannot tell us
Entirely in vitro study — no animal or human testing of the ssCGRP variant. The mathematical model did not fully reproduce ssCGRP binding behavior, suggesting additional complexity in the mechanism. Therapeutic potential of the ss variants is theoretical. Long-acting agonism at the CGRP receptor could have unwanted vascular effects.
How to read the evidence
This is a rigorous in vitro mechanistic study with sophisticated binding assays and mathematical modeling. It advances fundamental understanding of CGRP receptor pharmacology but has no direct clinical data yet.
When this study was published
Published in 2025, at the frontier of CGRP receptor pharmacology research.
The bigger picture
CGRP-targeting drugs (erenumab, fremanezumab, galcanezumab) have transformed migraine treatment. This work on the binding mechanism and ultrahigh-affinity variants represents the next frontier — potentially enabling long-acting formulations that require less frequent dosing and offer more precise receptor modulation.
Questions still open
- Could ssCGRP variants be developed into long-acting migraine therapeutics with less frequent dosing?
- What distinct binding mechanism does ssCGRP use that the mathematical model could not capture?
- Would ultrahigh-affinity CGRP agonists have clinical utility in conditions where CGRP signaling is deficient?
Common questions
How does this relate to current migraine drugs?
What is receptor residence time and why does it matter?
Read the original research
Characterization of the Two-Domain Peptide Binding Mechanism of the Human CGRP Receptor for CGRP and the Ultrahigh Affinity ssCGRP Variant.
Biochemistry, 64(8), 1770-1787
Citation
Babin, Katie M; Kilinc, Ceren; Gostynska, Sandra E; Dickson, Alex; Pioszak, Augen A. (2025). Characterization of the Two-Domain Peptide Binding Mechanism of the Human CGRP Receptor for CGRP and the Ultrahigh Affinity ssCGRP Variant.. Biochemistry, 64(8), 1770-1787. https://doi.org/10.1021/acs.biochem.4c00812